Interestingly, and in accordance with our work, recent publications have stated that in spite of promising preliminary findings, Darapladib treatment and associated Lp-PLA2 reduction failed to significantly reduce the incidence of myocardial infarction, stroke and cardiovascular death in a cohort of patients with coronary heart disease, when compared to a placebo treated control group following an extensive randomised, multicentre phase III clinical trial, [43]. This evidence concerns the gene PLA2G7 and stroke disorder.